369 related articles for article (PubMed ID: 37762648)
1. Emerging Immunotherapy Approaches for Treating Prostate Cancer.
Meng L; Yang Y; Mortazavi A; Zhang J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762648
[TBL] [Abstract][Full Text] [Related]
2. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
5. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
Comiskey MC; Dallos MC; Drake CG
Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
[TBL] [Abstract][Full Text] [Related]
7. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
9. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
11. [New forms of immunotherapy in uro-oncology : HLA-independent therapeutic approaches with bispecific antibodies and CAR T cells].
Krebs M; Chatterjee M; Kübler H; Kalogirou C
Urologie; 2023 Jul; 62(7):685-690. PubMed ID: 37341719
[TBL] [Abstract][Full Text] [Related]
12. The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.
Nath K; Mailankody S; Usmani SZ
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1201-1214. PubMed ID: 37330347
[TBL] [Abstract][Full Text] [Related]
13. Revisiting Immunotherapy: A Focus on Prostate Cancer.
Cha HR; Lee JH; Ponnazhagan S
Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.
Gerritsen WR; Sharma P
J Clin Immunol; 2012 Feb; 32(1):25-35. PubMed ID: 22048979
[TBL] [Abstract][Full Text] [Related]
15. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.
Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X
Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649
[TBL] [Abstract][Full Text] [Related]
17. Emerging immunological strategies: recent advances and future directions.
Zhao H; Luo F; Xue J; Li S; Xu RH
Front Med; 2021 Dec; 15(6):805-828. PubMed ID: 34874513
[TBL] [Abstract][Full Text] [Related]
18. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
19. [Targeted molecular therapy and immunotherapy for prostate cancer].
Grüllich C; Nößner E; Pfister D; Grünwald V
Urologe A; 2020 Jun; 59(6):687-694. PubMed ID: 32303774
[TBL] [Abstract][Full Text] [Related]
20. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]